<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038870</url>
  </required_header>
  <id_info>
    <org_study_id>ID99-075</org_study_id>
    <nct_id>NCT00038870</nct_id>
  </id_info>
  <brief_title>Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes</brief_title>
  <official_title>Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immunex Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Determine the feasibility of generation of autologous Acute Myelogenous Leukemia (AML)&#xD;
           or Chronic Myelogenous Leukemia in myeloid blast crisis (CML/BC) derived dendritic cell&#xD;
           activated lymphocytes (DC/AL) in poor prognosis patients.&#xD;
&#xD;
        2. Determine the toxicity of autologous leukemia derived dendritic cell activated&#xD;
           lymphocytes (DC/AL) in patients with AML or CML/BC.&#xD;
&#xD;
        3. Quantitate circulating immune effector cells in patients after infusion of DC/AL.&#xD;
&#xD;
        4. Record the efficacy of AML or CML/BC derived dendritic cells and activated lymphocytes&#xD;
           in promoting and sustaining remission in patients with AML or CML/BC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most patients relapsing with AML either fail to achieve second remission or have only brief&#xD;
      remissions. Patients more than 60 years of age or having histories of antecedent&#xD;
      hematological disorders, prior chemotherapy, or poor risk cytogenetics have generally only&#xD;
      short remissions and as a group have two year survivals of less than 10%. Equally patients&#xD;
      with myeloid blast crisis of CML often fail to achieve remission or have responses of only&#xD;
      brief duration. Laboratory studies have shown that AML leukemic blasts may be induced in&#xD;
      culture to differentiate into dendritic cells which in turn may be used activate autologous&#xD;
      lymphocytes to acquire leukemia specific cytotoxicity. This trial will assess the feasibility&#xD;
      of generation of dendritic cell activated lymphocytes, and toxicity and efficacy of these&#xD;
      activated cells given after reinduction chemotherapy. Before this study begins some toxicity&#xD;
      information will have been generated in a trial of similar cells given to CML patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Slow accrual.&#xD;
  </why_stopped>
  <start_date type="Actual">January 31, 2001</start_date>
  <completion_date type="Actual">January 14, 2003</completion_date>
  <primary_completion_date type="Actual">January 14, 2003</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Dendritic Cell Activated Lymphocytes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dendritic Cell Activated Lymphocyte</intervention_name>
    <arm_group_label>Dendritic Cell Activated Lymphocytes</arm_group_label>
    <other_name>autologous leukemia derived dendritic cell activated lymphocytes</other_name>
    <other_name>DC/AL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  AML patients either after first relapse or at diagnosis a) with high-risk cytogenetics&#xD;
             such as -7, -5, +8, chromosome 9 or 11 abnormality, or b) WBC &gt; 50,000, or c) age &gt; 60&#xD;
             years*.&#xD;
&#xD;
          -  AML patients are eligible for cell collection if they have &gt; 1000 circulating&#xD;
             blasts/mm at diagnosis.&#xD;
&#xD;
          -  CML patients in myeloid blast crisis with &gt; 1000 circulating blasts/mm.&#xD;
&#xD;
          -  Creatinine &lt;2, Bilirubin &lt;3.&#xD;
&#xD;
          -  Age &gt;18.&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  Factors which would prevent the patient from receiving or cooperating with the full&#xD;
             course of therapy or understanding the informed consent procedure.&#xD;
&#xD;
          -  Concurrent or expected need for therapy with corticosteroids.&#xD;
&#xD;
          -  Positive antibody to human immunodeficiency virus I.&#xD;
&#xD;
          -  Acute promyelocytic Leukemia (FAB-M3).&#xD;
&#xD;
          -  History of overt cardiac failure, systemic autoimmune disease or expected need for&#xD;
             steroid therapy.&#xD;
&#xD;
               -  Patients &gt;60 will be eligible for study but if found to have good prognosis&#xD;
                  cytogenetics (inversion (16) or t(8;21)) will subsequently be withdrawn from&#xD;
                  study and treated off protocol without infusion of autologous leukemia derived&#xD;
                  cells.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Champlin, MD,BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>June 5, 2002</study_first_submitted>
  <study_first_submitted_qc>June 6, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2002</study_first_posted>
  <last_update_submitted>October 24, 2018</last_update_submitted>
  <last_update_submitted_qc>October 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>CML</keyword>
  <keyword>Dendritic Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

